Government Contracts For Biodefense: The Benefits and Risks. Robert V. House, PhD, FATS, Senior Vice President of Government Contracts at Ology Bioservices shares his thoughts on the benefits of Government Contracting in [...]
CEPI awards up to US$43.6 million to Public Health Vaccines, LLC. for development of a single-dose Nipah virus vaccine candidate Public Health Vaccine, LLC. will partner with Crozet Biopharma to develop the Nipah [...]
Blue Water Vaccines, Developing Universal Flu Vaccine, to Partner With Ology Bioservices Inc. PRESS RELEASE UPDATED: AUG 7, 2019 CINCINNATI, August 7, 2019 (Newswire.com) - Blue Water Vaccines, a Cincinnati-based biotechnology startup, [...]
Tomic MT, Espinoza Y, Martinez Z, et al. Monoclonal Antibody Combinations Prevent Serotype A and Serotype B Inhalational Botulism in a Guinea Pig Model. Toxins 2019, 11(4), 208; https://doi.org/10.3390/toxins11040208. Read More > [...]
Nanotherapeutics, Inc., an integrated biopharmaceutical company with a focus on advanced development and manufacturing, announced today that it has secured a $28.5 million debt financing from White Oak Global Advisors, LLC. The funds will support the completion of the Company’s 180,000 sq. ft. flexible biologics manufacturing facility located in Alachua.
The NANO-ADM (Advanced Development and Manufacturing) facility, as it is known, will expand Nanotherapeutics’ core competencies in the development and cGMP manufacture of preclinical and clinical stage biopharmaceutical products. The Company provides a full range of drug development services and intends to further capitalize on its capabilities through partnerships with government and established companies, as well as continuing to fund the development of its internal pipeline.
Tomic MT, Espinoza Y, Martinez Z, et al. Monoclonal Antibody Combinations Prevent Serotype A and Serotype B Inhalational Botulism in a Guinea Pig Model. Toxins 2019, 11(4), 208; https://doi.org/10.3390/toxins11040208.
Barrett PN, Terpening SJ, Snow D, Cobb RR, Kistner O. Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases. Expert Review of Vaccines. 2017;16(9):883-894.
These are unprecedented times as we respond to avoid the spread of COVID-19, a novel coronavirus that has challenged our routine life. First and foremost, all of us at Ology Bioservices, Inc. hope you and your family members are well, healthy, and safe from harm’s way.
I am reaching out to inform you of steps we are taking to protect our staff, operations and importantly, your ongoing projects at Ology Bio during this time. Our goal is to be prepared to continue serving our clients during this time of uncertainty and confusion. In order to protect our employees and facility, and to keep your projects moving forward, we have implemented the following activities:
Increased our supplies of commonly used laboratory and manufacturing materials, well in advance of the declaration of a pandemic.
Implemented a New Visitor Policy at all locations to further protect the facilities and employees.
Service personnel, vendors, contractors only allowed in our facilities for highly specialized activities.
Persons entering our facilities must sanitize their hands before leaving the entry lobby.
Expanded our IT structure to allow employees with the ability to “work from home” wherever possible.
Providing daycare resources for critical personnel who must conduct their jobs on-site (for example engineering manufacturing, process development and quality).
Cancelled non-essential business travel for all employees of Ology Bioservices.
Cancelled or rescheduled larger meetings or gatherings.
There will be no disruption in communicating with Ology Bio personnel, and our offices will remain open. However, the limited number of personnel physically at our locations will mainly consist of those involved in supporting the process development and manufacturing of our customer’s biological products. Be assured that you will be able to reach all employees through their direct phone lines and email regardless of their location during this crisis.
The entire leadership team at Ology Bioservices remain committed to the health and safety of our employees and our commitments to the customers we serve. This nation has a history of strength and resilience and I am certain that together we will successfully navigate these challenges.